GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology.
Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.
The planned sequencing platform will be used for both exome and whole-genome sequencing research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry.
The company will work with the investigators to examine whether levels of the microRNA can predict patient outcomes to different anti-EGRF therapies.
The hospital will use the new methods with jointly developed bioinformatic analysis techniques to rapidly interpret genomic data.
IntegraGen will conduct sequencing for theNationalReferenceCenterand the microbiological collections at Institut Pasteur.
Genoma will commercialize the Arisk test outside the US and will provide genetic consulting services and diagnostics services to children with ASD and their parents.
The partners will try to validate the ability of has-miR-31-3p to predict which patients may benefit from anti-EGFR therapy.
The signatures involve a panel of genes that help researchers to distinguish between benign and malignant liver tumors and identify histological subtypes
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.